{"filing":{"accession_number":"0001493152-26-034183","cik":"0001712762","ticker":"BIAFW","company_name":"bioAffinity Technologies, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226034183/form8-k.htm"},"events":[{"id":19365,"run_id":17426,"accession_number":"0001493152-26-034183","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"bioAffinity announced a strategic collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The agreement integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic platform to create high-throughput laboratory tests. This is a material operational and strategic partnership affecting the company's product development roadmap and market positioning in a large therapeutic market ($108B+ projected by 2026), but it does not fit the specific categories of M\u0026A activity, debt issuance, or other defined event types—it is a material business collaboration and partnership milestone.","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":18438,"accession_number":"0001493152-26-034183","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"bioAffinity announced a strategic collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The agreement integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic platform to create high-throughput laboratory tests. This is a material operational and strategic partnership affecting the company's product development roadmap and market positioning in a large therapeutic market ($108B+ projected by 2026), but it does not fit the specific categories of M\u0026A activity, debt issuance, or other defined event types—it is a material business collaboration and partnership milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:31:44.945504+00:00","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-07-22"}]}